1. Home
  2. EXAS vs ATI Comparison

EXAS vs ATI Comparison

Compare EXAS & ATI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EXAS
  • ATI
  • Stock Information
  • Founded
  • EXAS 1995
  • ATI 1960
  • Country
  • EXAS United States
  • ATI United States
  • Employees
  • EXAS N/A
  • ATI N/A
  • Industry
  • EXAS Medical Specialities
  • ATI Steel/Iron Ore
  • Sector
  • EXAS Health Care
  • ATI Industrials
  • Exchange
  • EXAS Nasdaq
  • ATI Nasdaq
  • Market Cap
  • EXAS 11.0B
  • ATI 11.2B
  • IPO Year
  • EXAS N/A
  • ATI N/A
  • Fundamental
  • Price
  • EXAS $64.82
  • ATI $89.71
  • Analyst Decision
  • EXAS Strong Buy
  • ATI Strong Buy
  • Analyst Count
  • EXAS 21
  • ATI 7
  • Target Price
  • EXAS $69.24
  • ATI $99.67
  • AVG Volume (30 Days)
  • EXAS 2.0M
  • ATI 1.5M
  • Earning Date
  • EXAS 11-03-2025
  • ATI 10-28-2025
  • Dividend Yield
  • EXAS N/A
  • ATI N/A
  • EPS Growth
  • EXAS N/A
  • ATI 9.13
  • EPS
  • EXAS N/A
  • ATI 2.89
  • Revenue
  • EXAS $2,939,949,000.00
  • ATI $4,508,700,000.00
  • Revenue This Year
  • EXAS $16.68
  • ATI $7.22
  • Revenue Next Year
  • EXAS $12.12
  • ATI $7.25
  • P/E Ratio
  • EXAS N/A
  • ATI $30.83
  • Revenue Growth
  • EXAS 12.55
  • ATI 6.64
  • 52 Week Low
  • EXAS $38.81
  • ATI $39.23
  • 52 Week High
  • EXAS $72.83
  • ATI $96.20
  • Technical
  • Relative Strength Index (RSI)
  • EXAS 81.05
  • ATI 65.07
  • Support Level
  • EXAS $63.05
  • ATI $81.34
  • Resistance Level
  • EXAS $62.31
  • ATI $86.32
  • Average True Range (ATR)
  • EXAS 1.57
  • ATI 3.01
  • MACD
  • EXAS 0.27
  • ATI 0.54
  • Stochastic Oscillator
  • EXAS 92.60
  • ATI 88.38

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

About ATI ATI Inc.

ATI Inc supplies specialty metals to various end markets, including aerospace and defense, oil and gas, automotive, and electrical energy, among many others. The company's operating segment includes High-Performance Materials and Components and Advanced Alloys and Solutions. The majority of revenue is from the High-Performance Materials segment. The High-Performance Materials segment is focused on a wide range of high-performance specialty materials, parts, and components for several the majority of end markets, including the aerospace & defense, medical, and energy markets. Geographically, it operates in the United States, China, the United Kingdom, Germany, France, Canada, and Others, the majority is from the United States.

Share on Social Networks: